Endocrine Abstracts

Hormone dependent breast cancer is preferentially treated with Tamoxifen (TAM), an Estrogen Receptor antagonist. Although the initial response to TAM is tumour regression the majority of patients eventually relapse. Understanding the mechanisms that contribute to this resistant phenotype may influence the success of patient response to TAM and prevention of recurrence.A role for ER coactivator and corepressor proteins has been suggested to contribute to...